High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors
Top Cited Papers
- 20 January 2004
- Vol. 100 (3), 612-620
- https://doi.org/10.1002/cncr.11937
Abstract
BACKGROUND Desmoid tumors are mesenchymal nonmetastasizing neoplasms. Although rare in the general population, they are a common extracolonic manifestation of familial adenomatous polyposis (FAP). Because of high tumor recurrence rates, surgery has been less than satisfactory in the treatment of desmoid tumors. In the current study, high doses of tamoxifen in combination with sulindac were used to treat severe desmoid tumors to avoid surgery. METHODS Since 1992, 25 patients at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of tamoxifen and sulindac. In the current study, 17 patients with FAP‐associated and 8 patients with sporadic desmoid tumors received 120 mg of tamoxifen and 300 mg of sulindac daily. Every 6 months, the protracted course of desmoid growth was measured by computed tomography and/or magnetic resonance imaging scans. Tumor responses were characterized as progressive disease, stable disease (SD), partial regression (PR), and complete regression (CR). RESULTS Of the group of patients who received tamoxifen and sulindac as a primary treatment, all three patients with sporadic desmoid tumors demonstrated cessation of growth, and 10 of the 13 patients with FAP‐associated tumors achieved either a PR or CR. In the sporadic desmoid tumor group, eight of nine patients developed tumor recurrences after undergoingsurgery at other institutions. Of these, two patients had SD and two patients had a PR to CR. CONCLUSIONS The patients with desmoid tumors who were managed conservatively with high‐dose tamoxifen and sulindac had the best outcome. Desmoid tumor recurrence after surgery was high and in the FAP‐associated tumor group, therapy with tamoxifen and sulindac was found to be less successful. Based on this experience, the authors recommended high‐dose tamoxifen and sulindac as the primary treatment for patients with FAP‐associated desmoid tumors. However, to our knowledge, the best approach after surgical intervention for patients with sporadic desmoid tumors remains to be determined. Cancer 2004. © 2003 American Cancer Society.Keywords
This publication has 36 references indexed in Scilit:
- Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposisInternational Journal of Cancer, 2001
- Desmoid tumours complicating familial adenomatous polyposisBritish Journal of Surgery, 1999
- Desmoids in familial adenomatous polyposisBritish Journal of Surgery, 1996
- Desmoid tumours treated with triphenylethylenesEuropean Journal of Cancer, 1992
- The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposisCancer, 1987
- Occurrence of desmoids in patients with familial adenomatous polyposis of the colonAmerican Journal of Medical Genetics, 1987
- Desmoid Tumors in Familial Polyposis ColiAnnals of Surgery, 1986
- Estrogen and antiestrogen binding sites in desmoid tumorsEuropean Journal of Cancer and Clinical Oncology, 1986
- Mesenteric desmoid tumor in Gardner's syndrome treated by sulindacDiseases of the Colon & Rectum, 1984
- Multiple polyposis, gardner's syndrome and desmoid tumorsDiseases of the Colon & Rectum, 1958